Peripheral Arterial Disease Pipeline, Treatment Drugs, Clinical Trials, and Companies 2024

DelveInsight's, "Peripheral Arterial Disease Pipeline Insight 2024" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Peripheral Arterial Disease pipeline landscape. It covers the pipeline drug profiles, including Peripheral Arterial Disease clinical trials and nonclinical stage products. It also covers the Peripheral Arterial Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Peripheral Arterial Disease Pipeline. Dive into DelveInsight's comprehensive report today! @ Peripheral Arterial Disease Pipeline Outlook [https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Peripheral Arterial Disease Pipeline Report

* In September 2024:- Novartis Pharmaceuticals- The purpose of this study is to demonstrate the superiority of inclisiran compared to placebo, both on top of ongoing individually optimized lipid-lowering therapy (LLT), on reaching a participant's LDL-C target (< 55 mg/dL or < 70 mg/dL, depending on the cardiovascular risk category, according to the 2019 ESC/EAS guidelines for the management of dyslipidemias as well as on patient-relevant safety, tolerability outcomes and quality of life.
* In September 2024:- CSL Behring- This is a 2-part (phase 2b/3) prospective, interventional, multicenter, randomized, double blind, placebo controlled study. Part 1 (phase 2b) is a dose-finding study for CSL300 vs placebo. Part 2 (phase 3) aims to assess the efficacy of CSL300 on CV outcomes and safety in subjects with ASCVD or diabetes mellitus and evidence of systemic inflammation who are undergoing maintenance dialysis.
* DelveInsight's Peripheral Arterial Disease pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Peripheral Arterial Disease treatment.
* The leading Peripheral Arterial Disease Companies such as Novo Nordisk, Helixmith, AdvanceCor, Venturis Therapeutics, VivaCell Biotechnology, Humacyte, Bayer, Vasa Therapeutics , and others.
* Promising Peripheral Arterial Disease Therapies such as Inclisiran Sodium, CSL300, Rivaroxaban 2.5mg, Temsirolimus, Sarpogrelate Sustained Release/Aspirin, NL003 , and others

Stay ahead with the most recent pipeline outlook for Peripheral Arterial Disease. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Peripheral Arterial Disease Treatment Drugs [https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Peripheral Arterial Disease Emerging Drugs Profile

* Semaglutide: Novo Nordisk

Semaglutide is a long-acting oral GLP-1 analogue being developed and investigated by Novo Nordisk. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with Peripheral Artery Disease.

* VM202: Helixmith

VM202 is an investigational gene therapy being developed by Helixmith, formerly known as ViroMed. Helixmith's non-viral plasmid DNA product, Engensis, is designed to express recombinant HGF protein in nerve and Schwann cells to promote nerve system regeneration and induce the formation of microvascular blood vessels. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Peripheral Artery Disease.

* Revacept: AdvanceCor

Revacept is the first Fc-fusion protein to be used as pharmaceutical in stroke and heart attack. With its GPVI component, Revacept binds to damaged blood vessel walls, covers them and thus forms a kind of vascular patch. This prevents the formation of thrombi in the arteries. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Peripheral Artery Disease.

Explore groundbreaking therapies and clinical trials in the Peripheral Arterial Disease Pipeline. Access DelveInsight's detailed report now! @ New Peripheral Arterial Disease Drugs [https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Peripheral Arterial Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

Peripheral Arterial Disease Products have been categorized under various Molecule types such as

* Monoclonal antibody
* Small molecule
* Peptide

Unveil the future of Peripheral Arterial Disease Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Peripheral Arterial Disease Market Drivers and Barriers [https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Peripheral Arterial Disease Pipeline Report

* Coverage- Global
* Peripheral Arterial Disease Companies- Novo Nordisk, Helixmith, AdvanceCor, Venturis Therapeutics, VivaCell Biotechnology, Humacyte, Bayer, Vasa Therapeutics, and others.
* Peripheral Arterial Disease Therapies- Inclisiran Sodium, CSL300, Rivaroxaban 2.5mg, Temsirolimus, Sarpogrelate Sustained Release/Aspirin, NL003, and others
* Peripheral Arterial Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Peripheral Arterial Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Peripheral Arterial Disease Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Peripheral Arterial Disease Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Peripheral Arterial Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Peripheral Arterial Disease - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Peripheral Arterial Disease Collaboration Deals
* Late Stage Products (Phase III)
* Semaglutide: Novo Nordisk
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* VM202: Helixmith
* Drug profiles in the detailed report.....
* Early stage products (Phase I)
* Revacept: AdvanceCor
* Drug profiles in the detailed report.....
* Inactive Products
* Peripheral Arterial Disease Key Companies
* Peripheral Arterial Disease Key Products
* Peripheral Arterial Disease Unmet Needs
* Peripheral Arterial Disease Market Drivers and Barriers
* Peripheral Arterial Disease Future Perspectives and Conclusion
* Peripheral Arterial Disease Analyst Views
* Peripheral Arterial Disease Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=peripheral-arterial-disease-pipeline-treatment-drugs-clinical-trials-and-companies-2024]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.